Non-sleepy obstructive sleep apnoea: to treat or not to treat?

Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA an...

Descripción completa

Detalles Bibliográficos
Autores principales: Altintas, Nejat, Riha, Renata L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2019
Materias:
Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488974/
https://www.ncbi.nlm.nih.gov/pubmed/31871125
http://dx.doi.org/10.1183/16000617.0031-2019
Descripción
Sumario:Non-sleepy obstructive sleep apnoea (OSA) is thought to have a prevalence of around 20–25% in industrialised countries. However, the question of whether it should be routinely treated or not is controversial. This review collates the results from recent randomised controlled trials addressing OSA and examines whether treating the condition leads to improvements in quality of life and reduced cardiometabolic dysfunction, comorbidities generally attributed to untreated obstructive sleep apnoea/hypopnoea syndrome.

Ejemplares similares